SecBot SecBot
PRESS-RELEASE ·Filed Nov 16, 2026

AEON

AEON Biopharma Inc
NEUTRAL
Impact 5/10
Processed7h 18m ago Wirepress-3404147
Press release · Earnings

Price Chart

Loading chart...

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3404147

Track record

22 reports on AEON

Performance horizon

8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +44.50% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 5/10 Viewing Entry price pending
  3. Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $0.1610 Now $0.1410 −12.42% settles Nov 23
  4. Nov 10, 20266d ago SC 13D/A Neutral 3/10 Entry $0.1793 Now $0.1410 −21.36% settles Nov 17
  5. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1818 to $0.1407 Now $0.1410 −22.44% ▼ −22.61% −20.91% vs SPY
  6. Nov 3, 202613d ago 8-K Neutral 4/10 Entry $0.2122 to $0.1793 Now $0.1410 −33.55% ▼ −15.50% −14.92% vs SPY
  7. Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $0.2483 to $0.2122 Now $0.1410 −43.21% ▼ −14.54% −12.55% vs SPY
  8. Oct 23, 202624d ago 8-K Neutral 4/10 Entry $0.2400 to $0.2740 Now $0.1410 −41.25% ▲ +14.17% +15.43% vs SPY
  9. Sep 30, 20266w ago 8-K Bullish 7/10 Entry $0.3000 to $0.3110 Now $0.1410 −53.00% ▲ +3.67% +1.75% vs SPY
  10. Aug 21, 202612w ago 3 Neutral Not scored Entry $0.1974 to $0.2959 Now $0.1410 −28.57% ▲ +49.90% +49.43% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (9h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026

Fresh AEON Intelligence

Analysis is for subscribers only.

Subscribe for Full Access